Treatment of Chronic Posterior Laryngitis With Esomeprazole

Vaezi, Michael F.; Richter, Joel E.; Stasney, C. Richard; Spiegel, Joseph R.; Iannuzzi, Ralph A.; Crawley, Joseph A.; Hwang, Clara; Sostek, Mark; Shaker, Reza

doi:10.1097/01.mlg.0000192173.00498.ba

Cited by 304 publications

(271 citation statements)

References 25 publications

Supporting

Mentioning

255

Contrasting

Unclassified

Order By: Relevance

“…In a large randomized, placebo-controlled, multicenter trial of 145 patients, Vaezi et al 75 were unable to demonstrate that 40 mg esomeprazole twice daily for 16 weeks was better than placebo for symptom resolution or improvement in laryngeal signs of laryngopharyngeal reflux. A subsequent meta-analysis of the placebo-controlled studies in laryngopharyngeal reflux has reported minimal therapeutic benefit of PPIs over placebo.…”

Section: -74mentioning

confidence: 99%

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Dickman

Maradey–Romero

Gingold‐Belfer

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is a highly prevalent gastrointestinal disorder. Proton pump inhibitors have profoundly revolutionized the treatment of GERD. However, several areas of unmet need persist despite marked improvements in the therapeutic management of GERD. These include the advanced grades of erosive esophagitis, nonerosive reflux disease, maintenance treatment of erosive esophagitis, refractory GERD, postprandial heartburn, atypical and extraesophageal manifestations of GERD, Barrett's esophagus, chronic protein pump inhibitor treatment, and post-bariatric surgery GERD. Consequently, any future development of novel therapeutic modalities for GERD (medical, endoscopic, or surgical), would likely focus on the aforementioned areas of unmet need.

show abstract

Section: -74mentioning

confidence: 99%

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Dickman

Maradey–Romero

Gingold‐Belfer

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

“…The RFS is an 8-item clinical severity scale based on findings during fiberoptic laryngoscopy. However, this RFS system has been criticized to have high inter-or intra-observer variability and low specificity for reflux laryngitis [6,10,19] . Therefore, it is very important to exclude meticulously other potential etiologies that can lead to laryngeal irritation.…”

Section: Discussionmentioning

confidence: 99%

“…Patients were excluded from the study if they had a history of respiratory or gastrointestinal malignancy; radiation therapy to the head and neck, lung, or gastrointestinal tract; gastroesophageal surgery; use of H 2 -receptor antagonists or proton pump inhibitors in previous 1 mo; past or present smoker; excessive alcohol consumption; chronic cough attributable to known chronic pulmonary or tracheobronchial disease; professional voice users (e.g. singer, teacher); excessive voice use; exposure to occupational or environmental pollutants; history of seasonal allergic rhinitis; pharyngolaryngeal infection in the previous 3 mo; tracheal intubation in the previous 12 mo and use of inhaled corticosteroids [10,11] .…”

Section: Recruitment Of Patientsmentioning

confidence: 99%

Laryngopharyngeal reflux in patients with reflux esophagitis

Lai

Wang²,

Lin³

2008

WJG

View full text Add to dashboard Cite

“…Attempts were made to contact study authors for additional information needed for full analysis of their data. [12][13][14][15][16] Results…”

Section: Analysis Of Therapeutic Gainmentioning

confidence: 99%

Response of Chronic Cough to Acid-Suppressive Therapy in Patients With Gastroesophageal Reflux Disease

Kahrilas

Howden

Hughes

et al. 2013

Chest

157

100

View full text Add to dashboard Cite

Background: Epidemiologic and physiologic studies suggest an association between gastroesophageal refl ux disease (GERD) and chronic cough. However, the benefi t of antirefl ux therapy for chronic cough remains unclear, with most relevant trials reporting negative fi ndings. This systematic review aimed to reevaluate the response of chronic cough to antirefl ux therapy in trials that allowed us to distinguish patients with or without objective evidence of GERD. Methods: PubMed and Embase systematic searches identifi ed clinical trials reporting cough response to antirefl ux therapy. Datasets were derived from trials that used pH-metry to characterize patients with chronic cough. Results: Nine randomized controlled trials of varied design that treated patients with acid suppression were identifi ed (eight used proton pump inhibitors [PPIs], one used ranitidine). Datasets from two crossover studies showed that PPIs signifi cantly improved cough relative to placebo, albeit only in the arm receiving placebo fi rst. Therapeutic gain in seven datasets was greater in patients with pathologic esophageal acid exposure (range, 12.5%-35.8%) than in those without (range, 0.0%-8.6%), with no overlap between groups. Conclusions: A therapeutic benefi t for acid-suppressive therapy in patients with chronic cough cannot be dismissed. However, evidence suggests that rigorous patient selection is necessary to identify patient populations likely to be responsive, using physiologically timed cough events during refl ux testing, minimal patient exclusion because of presumptive alternative diagnoses, and appropriate power to detect a modest therapeutic gain. Only then can we hope to resolve this vexing clinical management problem. CHEST 2013; 143(3):605-612Abbreviations: GERD 5 gastroesophageal refl ux disease; LPR 5 laryngopharyngeal refl ux; PPI 5 proton pump inhibitor

show abstract

Treatment of Chronic Posterior Laryngitis With Esomeprazole

Abstract: This study provides no evidence of a therapeutic benefit of treatment with esomeprazole 40 mg twice daily for 16 weeks compared with placebo for signs and symptoms associated with CPL.

Cited by 304 publications

References 25 publications

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Laryngopharyngeal reflux in patients with reflux esophagitis

Response of Chronic Cough to Acid-Suppressive Therapy in Patients With Gastroesophageal Reflux Disease

Contact Info

Product

Resources

About